Psoriatic arthritis: Difference between revisions

Jump to navigation Jump to search
Line 143: Line 143:
*** Preferred regimen (3): [[Ibuprofen]]: Max dose of up to 2400 mg/day
*** Preferred regimen (3): [[Ibuprofen]]: Max dose of up to 2400 mg/day
**** Adverese effects of [[Non-steroidal anti-inflammatory drug|Nonsteroidal antiinflammatory drugs]] include increased cardiovascular risk, [[gastritis]], [[Peptic ulcer|ulcers]] and [[Renal insufficiency|low renal clearance]].
**** Adverese effects of [[Non-steroidal anti-inflammatory drug|Nonsteroidal antiinflammatory drugs]] include increased cardiovascular risk, [[gastritis]], [[Peptic ulcer|ulcers]] and [[Renal insufficiency|low renal clearance]].
** '''Moderate to severe disease: Conventional synthetic disease modifying anti rheumatic drugs (DMARDs) may be considered in patients with moderate to severe active peripheral arthritis. These are also considered in patients who are resistant or not responding to NSAIDs, and local corticosteroid injections.
*** Preferred regimen
* '''Non pharmacologic therapy''':
* '''Non pharmacologic therapy''':
** [[Physical exercise|Exercise]]
** [[Physical exercise|Exercise]]
** [[Weight]] reduction
** [[Weight]] reduction
** [[Physical therapy]]
** [[Physical therapy]]
** [[Occupational therapy]]
** Educating the [[patient]] about [[disease]] course,  [[joint]] protection and [[Comorbidity|comorbid]] conditions.
** Educating the [[patient]] about [[disease]] course,  [[joint]] protection and [[Comorbidity|comorbid]] conditions.
** [[Orthotics]]
** [[Orthotics]]

Revision as of 21:15, 17 April 2018

WikiDoc Resources for Psoriatic arthritis

Articles

Most recent articles on Psoriatic arthritis

Most cited articles on Psoriatic arthritis

Review articles on Psoriatic arthritis

Articles on Psoriatic arthritis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Psoriatic arthritis

Images of Psoriatic arthritis

Photos of Psoriatic arthritis

Podcasts & MP3s on Psoriatic arthritis

Videos on Psoriatic arthritis

Evidence Based Medicine

Cochrane Collaboration on Psoriatic arthritis

Bandolier on Psoriatic arthritis

TRIP on Psoriatic arthritis

Clinical Trials

Ongoing Trials on Psoriatic arthritis at Clinical Trials.gov

Trial results on Psoriatic arthritis

Clinical Trials on Psoriatic arthritis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Psoriatic arthritis

NICE Guidance on Psoriatic arthritis

NHS PRODIGY Guidance

FDA on Psoriatic arthritis

CDC on Psoriatic arthritis

Books

Books on Psoriatic arthritis

News

Psoriatic arthritis in the news

Be alerted to news on Psoriatic arthritis

News trends on Psoriatic arthritis

Commentary

Blogs on Psoriatic arthritis

Definitions

Definitions of Psoriatic arthritis

Patient Resources / Community

Patient resources on Psoriatic arthritis

Discussion groups on Psoriatic arthritis

Patient Handouts on Psoriatic arthritis

Directions to Hospitals Treating Psoriatic arthritis

Risk calculators and risk factors for Psoriatic arthritis

Healthcare Provider Resources

Symptoms of Psoriatic arthritis

Causes & Risk Factors for Psoriatic arthritis

Diagnostic studies for Psoriatic arthritis

Treatment of Psoriatic arthritis

Continuing Medical Education (CME)

CME Programs on Psoriatic arthritis

International

Psoriatic arthritis en Espanol

Psoriatic arthritis en Francais

Business

Psoriatic arthritis in the Marketplace

Patents on Psoriatic arthritis

Experimental / Informatics

List of terms related to Psoriatic arthritis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Chandrakala Yannam, MD [2]

Overview

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Clinical Features

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • In general, there is no gender predilection to psoriatic arthritis.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

Imaging Findings

Psoriatic-arthritis of hands showing pencil-in-cup deformity - By Case courtesy of Dr Jeremy Jones, <a href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/8798">rID: 8798</a>
  • MRI:

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

  1. Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, Ramonda R, Todesco S (2007). "Laboratory findings in psoriatic arthritis". Reumatismo. 59 Suppl 1: 52–5. PMID 17828345.
  2. Johnson SR, Schentag CT, Gladman DD (May 2005). "Autoantibodies in biological agent naive patients with psoriatic arthritis". Ann. Rheum. Dis. 64 (5): 770–2. doi:10.1136/ard.2004.031286. PMC 1755477. PMID 15834057.
  3. Chandran V, Bull SB, Pellett FJ, Ayearst R, Rahman P, Gladman DD (October 2013). "Human leukocyte antigen alleles and susceptibility to psoriatic arthritis". Hum. Immunol. 74 (10): 1333–8. doi:10.1016/j.humimm.2013.07.014. PMID 23916976.
  4. Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, Gladman DD (January 2012). "Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis". Ann. Rheum. Dis. 71 (1): 50–5. doi:10.1136/ard.2011.155044. PMID 21900282.
  5. McGonagle D, Hermann KG, Tan AL (January 2015). "Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era". Rheumatology (Oxford). 54 (1): 29–38. doi:10.1093/rheumatology/keu328. PMC 4269795. PMID 25231177.
  6. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD (April 2006). "Clinical and radiological damage in psoriatic arthritis". Ann. Rheum. Dis. 65 (4): 478–81. doi:10.1136/ard.2005.039826. PMC 1798082. PMID 16126794.
  7. Haddad A, Chandran V (2013). "Arthritis mutilans". Curr Rheumatol Rep. 15 (4): 321. doi:10.1007/s11926-013-0321-7. PMID 23430715.
  8. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, Filipponi P, Marcolongo R (January 2001). "Bone mineral density in patients with psoriatic arthritis". J. Rheumatol. 28 (1): 138–43. PMID 11196516.
  9. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (March 2016). "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update". Ann. Rheum. Dis. 75 (3): 499–510. doi:10.1136/annrheumdis-2015-208337. PMID 26644232.
  10. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P (January 2012). "European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies". Ann. Rheum. Dis. 71 (1): 4–12. doi:10.1136/annrheumdis-2011-200350. PMID 21953336.
  11. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ (September 2009). "Treatment recommendations for psoriatic arthritis". Ann. Rheum. Dis. 68 (9): 1387–94. doi:10.1136/ard.2008.094946. PMC 2719080. PMID 18952643.
  12. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R (July 2011). "Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions". J. Am. Acad. Dermatol. 65 (1): 137–74. doi:10.1016/j.jaad.2010.11.055. PMID 21306785.
  13. Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes IB, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh NJ (October 2013). "The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics". Rheumatology (Oxford). 52 (10): 1754–7. doi:10.1093/rheumatology/ket187. PMID 23887065.
  14. Nash P, Clegg DO (March 2005). "Psoriatic arthritis therapy: NSAIDs and traditional DMARDs". Ann. Rheum. Dis. 64 Suppl 2: ii74–7. doi:10.1136/ard.2004.030783. PMC 1766880. PMID 15708943.
  15. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I (2001). "The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide". Clin. Exp. Rheumatol. 19 (1 Suppl 22): S17–20. PMID 11296544.

Template:WS Template:WH